期刊文献+

人乳头瘤病毒6型L1基因的克隆及蛋白表达

Cloning and Expression of Human Papillomavirus Type 6 L1 Gene
下载PDF
导出
摘要 目的:在大肠杆菌中表达经密码子优化的人乳头瘤病毒6型(HPV6)L1的融合蛋白。方法:PCR方法扩增HPV6L1基因,测序及序列比对后,对基因进行密码子优化并合成优化后的基因HPV6 mL1,将其克隆入原核表达载体pGEX4T-1,IPTG诱导融合蛋白在大肠杆菌BL21(DE3)中表达,SDS-PAGE鉴定表达产物。结果:酶切和测序结果证实HPV6 mL1基因的原核表达载体构建正确;以1mmol/L IPTG于37℃诱导4h,蛋白以包涵体形式表达;表达产物的相对分子质量与预期值一致,为80000。结论:获得大肠杆菌表达的HPV6L1蛋白,为其结构功能研究和疫苗研发提供了基础。 Objective: To express optimized-code fusion protein L1 of human papillomavirus type 6 (HPV6) in E.coli BL21 (DE3). Methods: HPV6 L1 gene was amplified by PCR and the optimized-code HPV6 mL1 gene was synthesized basing on sequencing and sequence comparison. The HPV6 roLl gene was inserted into the prokaryotic vector pGEX4T-1 to construct the expression plasmid, and then the HPV6 taLl protein was expressed after induction of IPTG in E.coli BL21(DE3). The fusion protein was determined by SDS-PAGE. Results: Restriction enzyme digestion analysis and DNA sequencing showed that the prokaryotic expression system of HPV6 mL1 gene was constructed successfully. When induced by 1 mmol/L IPTG lasted 4 h at 37℃, fusion protein HPV6 L1 was expressed in inclusion body form. SDS-PAGE showed that the molecular weight of fusion protein was 80 kD and was identical with predict size. Conclusion: Fusion protein HPV6 L1 was obtained, which provides a basis for further vaccine and functional assay.
出处 《生物技术通讯》 CAS 2009年第4期495-497,共3页 Letters in Biotechnology
关键词 人乳头瘤病毒6型 L1基因 蛋白表达 human papillomavirus type 6 L1 gene protein expression
  • 相关文献

参考文献1

二级参考文献20

  • 1Karube A, Sasaki M, Tanaka H, et al. Human papillomavirus typel6 infection and the early onset of cervical cancer [ J ].Bioche Biophys Res Commun, 2004, 323 ( 2 ) :621-624.
  • 2Ault KA,Giuliano AR, Edwards RP,et al. A phase Ⅱ study to evaluate a human papillomavirus (HPV) type 18 LI VLP vaccine[ J ]. Vaccine, 2004, 22 (23-24) :3004-3007.
  • 3Matthews-Greer J, Rivette D, Reyes R,et al. Human papillomavirus detection : verification with cervical cytology [ J ]. Clin Lab Sci, 2004, 17( 1 ) :8-11.
  • 4Cox JT. Management of women with cervical cancer precursor lesions[ J]. Obstet Gynecol Clin North Am, 2002, 29 (4):787-816.
  • 5Nayar R, Tabbara SO. Atypical squamous cells:update on current comept[J]. Clin Lab Med,2003,23(3) :605-632.
  • 6Anderssons S, Rylander E, Larsson B,et al. The role of human papillomavirus in cervical carcinoma carcinogenesis [ J ]. Eur J Carcer, 2001,37(2) :246-250.
  • 7Wadler S,Levy D,Frederickson HL, A phase Ⅱ trial of IL-12 in patients with advanced cervical cancer: clinical and immunologic correlates, Eastern Cooperative Oncology Group study E1E96 [J]. Gynecol Oncol, 2004, 92(3) :957-964.
  • 8Fife KH, Wheeler CM,, Koutsky LA,et al. Dose-ranging studies of the safety and immuogecnicity of human papillomavirus Type11 and Type 16 virus-like particle candidate vaccines in yong healthy women[J]. Vaccine, 2004, 22(21-22):2943-2952,.
  • 9Stanley M. Genital human papillomavirus infections-current and prospective therapies[ J ]. J Nat Cancer Inst Monog,2003,31 :117-124.
  • 10Hallez S, Simon P, Maudoux F,et al. Phase Ⅰ/Ⅱ trial of immuunogenicity of a haman papillomavirus ( HPV ) type16E7 protein-based vaccine in women with oncogenic HPV-positive cervical intraepithelial neoplasia[J]. Cancer lmmunother, 2004,53 ( 7 ) :642-650.

共引文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部